| Stage | UHS | % of rev | HCA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $4.6B | 100.00% | $19.8B | 100.00% | HCA ×4.28 |
| Gross profit | $2.5B | 53.85% | $11.3B | 56.77% | HCA +2.9pp |
| Operating income | $517M | 11.14% | $3.0B | 14.90% | HCA +3.8pp |
| Pre-tax income | $479M | 10.33% | $2.4B | 11.94% | HCA +1.6pp |
| Net income | $365M | 7.86% | $1.8B | 9.32% | HCA +1.5pp |
| Stage | UHS | HCA | Gap · A − B |
|---|---|---|---|
| Revenue | $4.6B100.00% | $19.8B100.00% | HCA ×4.28 |
| Gross profit | 53.85%$2.5B | 56.77%$11.3B | HCA +2.9pp |
| Operating income | 11.14%$517M | 14.90%$3.0B | HCA +3.8pp |
| Pre-tax income | 10.33%$479M | 11.94%$2.4B | HCA +1.6pp |
| Net income |
| 7.86%$365M |
| 9.32%$1.8B |
| HCA +1.5pp |
No shared counterparties.